Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Gibson CM, et al. Among authors: mehran r. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Circulation. 2017. PMID: 27881555 Free PMC article. Clinical Trial.
Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study.
Mehran R, Aymong ED, Ashby DT, Fischell T, Whitworth H Jr, Siegel R, Thomas W, Wong SC, Narasimaiah R, Lansky AJ, Leon MB. Mehran R, et al. Circulation. 2003 Sep 2;108(9):1078-83. doi: 10.1161/01.CIR.0000086347.31341.F9. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925457 Clinical Trial.
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Among authors: mehran r. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis.
Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Fujii K, et al. Among authors: mehran r. Circulation. 2004 Mar 9;109(9):1085-8. doi: 10.1161/01.CIR.0000121327.67756.19. Epub 2004 Mar 1. Circulation. 2004. PMID: 14993129 Clinical Trial.
Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Lansky AJ, et al. Among authors: mehran r. Circulation. 2005 Apr 5;111(13):1611-8. doi: 10.1161/01.CIR.0000160362.55803.40. Circulation. 2005. PMID: 15811868 Clinical Trial.
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ; TAXUS-IV Investigators. Pinto DS, et al. Among authors: mehran r. J Am Coll Cardiol. 2006 Jul 4;48(1):32-6. doi: 10.1016/j.jacc.2006.02.060. Epub 2006 Jun 9. J Am Coll Cardiol. 2006. PMID: 16814645 Free article. Clinical Trial.
Clinical end points in coronary stent trials: a case for standardized definitions.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Cutlip DE, et al. Among authors: mehran r. Circulation. 2007 May 1;115(17):2344-51. doi: 10.1161/CIRCULATIONAHA.106.685313. Circulation. 2007. PMID: 17470709
Postmarket evaluation of breakthrough technologies.
Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW. Rao SV, et al. Among authors: mehran r. Am Heart J. 2008 Aug;156(2):201-8. doi: 10.1016/j.ahj.2008.01.036. Am Heart J. 2008. PMID: 18657647
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Pinto DS, et al. Among authors: mehran r. J Am Coll Cardiol. 2008 Nov 25;52(22):1758-68. doi: 10.1016/j.jacc.2008.08.021. J Am Coll Cardiol. 2008. PMID: 19022155 Free article. Clinical Trial.
1,789 results